Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study
| Autor: | Yasushi Sato, Tamotsu Sagawa, Hiroyuki Ohnuma, Junji Kato, Masahiro Hirakawa, Tetsuji Takayama, Koichi Okamoto, Koji Miyanishi, Ichiro Takemasa, Hiroshi Miyamoto, Yasuo Takahashi, Shohei Kikuchi, Takayuki Nobuoka |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Neutropenia medicine.medical_treatment Docetaxel Kaplan-Meier Estimate Toxicology Gastroenterology 03 medical and health sciences 0302 clinical medicine Stomach Neoplasms Internal medicine Ascites Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Adverse effect Peritoneal Neoplasms Aged Retrospective Studies Tegafur Pharmacology Chemotherapy Performance status business.industry Cancer Combination chemotherapy Nausea Middle Aged medicine.disease Anorexia Drug Combinations Oxonic Acid 030104 developmental biology Treatment Outcome Oncology Tolerability 030220 oncology & carcinogenesis Female medicine.symptom Cisplatin business medicine.drug |
| Zdroj: | Cancer chemotherapy and pharmacology. 81(3) |
| ISSN: | 1432-0843 |
| Popis: | Peritoneal metastasis (PM) in advanced or recurrent gastric cancer (AGC) is the most frequent cause of death from this disease. However, current treatments remain unsatisfactory. We previously conducted studies of docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for AGC. The aim of this study was to investigate the benefits and tolerability of DCS in PM patients. Patients were divided into three groups: patients without PM (non-PM); PM patients without ascites, or mild to moderate ascites (None–Mod); and PM patients with massive ascites (Massive). Patients received oral S-1 (40 mg/m2 b.i.d.) on days 1–14, and intravenous cisplatin (60 mg/m2) and docetaxel (50–60 mg/m2) on day 8 every 3 weeks. Drug exposure, adverse events, tumor response, progression-free and overall survival (OS) rates were evaluated. Of the 111 AGC patients who received DCS as first-line therapy, 37 cases had complicated PM, 15 of whom displayed massive ascites. The response rate for PM patients was 81.5%. Drug exposure and toxicities were not meaningfully different among the groups. The MSTs were also similar: 22.6 months for the non-PM, 21.7 months for the None–Mod PM, and 16.8 months for the Massive, respectively. Ten (27.0%) patients with PM achieved downstaging and underwent curative surgery, subsequently demonstrating an excellent MST of 28.0 months. An independent prognostic factor for OS, as revealed by multivariate analyses. was a good performance status. DCS is feasible and efficacious for AGC with PM, especially when patients present with a good PS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink